PL1687028T5 - Preparaty immunoglobulin o zwiększonej stabilności - Google Patents

Preparaty immunoglobulin o zwiększonej stabilności

Info

Publication number
PL1687028T5
PL1687028T5 PL04818790T PL04818790T PL1687028T5 PL 1687028 T5 PL1687028 T5 PL 1687028T5 PL 04818790 T PL04818790 T PL 04818790T PL 04818790 T PL04818790 T PL 04818790T PL 1687028 T5 PL1687028 T5 PL 1687028T5
Authority
PL
Poland
Prior art keywords
increased stability
immunoglobulin preparations
immunoglobulin
preparations
stability
Prior art date
Application number
PL04818790T
Other languages
English (en)
Other versions
PL1687028T3 (pl
Inventor
Reinhard Bolli
Gerhard Hodler
Regula Styger
Original Assignee
Csl Behring Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=34429394&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL1687028(T5) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Csl Behring Ag filed Critical Csl Behring Ag
Publication of PL1687028T3 publication Critical patent/PL1687028T3/pl
Publication of PL1687028T5 publication Critical patent/PL1687028T5/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies from serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/20—Antivirals for DNA viruses

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Dermatology (AREA)
  • Virology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
PL04818790T 2003-11-18 2004-11-17 Preparaty immunoglobulin o zwiększonej stabilności PL1687028T5 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP03026539A EP1532983A1 (en) 2003-11-18 2003-11-18 Immunoglobulin preparations having increased stability
EP04818790.0A EP1687028B2 (en) 2003-11-18 2004-11-17 Immunoglobulin preparations having increased stability
PCT/EP2004/013022 WO2005049078A2 (en) 2003-11-18 2004-11-17 Immunoglobulin preparations having increased stability

Publications (2)

Publication Number Publication Date
PL1687028T3 PL1687028T3 (pl) 2013-03-29
PL1687028T5 true PL1687028T5 (pl) 2016-05-31

Family

ID=34429394

Family Applications (2)

Application Number Title Priority Date Filing Date
PL04818790T PL1687028T5 (pl) 2003-11-18 2004-11-17 Preparaty immunoglobulin o zwiększonej stabilności
PL10177786.0T PL2364730T3 (pl) 2003-11-18 2004-11-17 Preparaty immunoglobulin o zwiększonej stabilności

Family Applications After (1)

Application Number Title Priority Date Filing Date
PL10177786.0T PL2364730T3 (pl) 2003-11-18 2004-11-17 Preparaty immunoglobulin o zwiększonej stabilności

Country Status (10)

Country Link
US (2) US8715652B2 (pl)
EP (3) EP1532983A1 (pl)
JP (1) JP4644203B2 (pl)
KR (3) KR20100090731A (pl)
AU (1) AU2004290899B2 (pl)
CA (1) CA2545939C (pl)
DK (2) DK1687028T4 (pl)
ES (2) ES2398241T5 (pl)
PL (2) PL1687028T5 (pl)
WO (1) WO2005049078A2 (pl)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060104968A1 (en) 2003-03-05 2006-05-18 Halozyme, Inc. Soluble glycosaminoglycanases and methods of preparing and using soluble glycosaminogly ycanases
EP1532983A1 (en) † 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
BRPI0611901A2 (pt) 2005-06-14 2012-08-28 Amgen, Inc composição, liofilizado, kit, e, processo para preparar uma composição
KR100784134B1 (ko) * 2006-10-09 2007-12-12 주식회사 대웅 상피세포성장인자를 함유하는 안정한 구내염 치료용 액상조성물
CA2790018C (en) * 2006-12-21 2015-02-03 Amgen Inc. Formulations
RU2476442C2 (ru) 2007-03-29 2013-02-27 Эббот Лэборетриз Кристаллические антитела против il-12 человека
EP2170268A2 (en) 2007-06-25 2010-04-07 Amgen, Inc. Compositions of specific binding agents to hepatocyte growth factor
US8420081B2 (en) * 2007-11-30 2013-04-16 Abbvie, Inc. Antibody formulations and methods of making same
US8883146B2 (en) 2007-11-30 2014-11-11 Abbvie Inc. Protein formulations and methods of making same
PE20091174A1 (es) * 2007-12-27 2009-08-03 Chugai Pharmaceutical Co Ltd Formulacion liquida con contenido de alta concentracion de anticuerpo
TWI489994B (zh) 2008-03-17 2015-07-01 Baxter Healthcare Sa 供免疫球蛋白及玻尿酸酶之皮下投藥之用的組合及方法
KR101668502B1 (ko) 2008-11-04 2016-10-21 아스카 세이야쿠 가부시키가이샤 난포자극호르몬 함유 수성 조성물
RU2011126338A (ru) * 2008-11-28 2013-01-10 Эбботт Лэборетриз Стабильные композиции антител и способы их стабилизации
EP3167875A1 (en) 2009-05-27 2017-05-17 Alkermes Pharma Ireland Limited Reduction of flake-like aggregation in nanoparticulate meloxicam compositions
HUE028832T2 (en) 2009-09-17 2017-01-30 Baxalta Inc Stable co-formulation of hyaluronidase and immunoglobulin, as well as a process for its preparation
WO2011095543A1 (en) * 2010-02-04 2011-08-11 Csl Behring Ag Immunoglobulin preparation
EP2361636A1 (en) 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation
PT3345615T (pt) 2010-03-01 2020-01-17 Bayer Healthcare Llc Anticorpos monoclonais otimizados contra inibidor da via do fator tecidual (tfpi)
WO2011121559A2 (en) 2010-03-31 2011-10-06 Universite De Geneve Stabilized antibody preparations and uses thereof
US20130028920A1 (en) 2010-03-31 2013-01-31 Universite De Geneve Stabilized antibody preparations and uses thereof
GB201006753D0 (en) 2010-04-22 2010-06-09 Biotest Ag Process for preparing an immunolobulin composition
FR2961107B1 (fr) 2010-06-15 2012-07-27 Lab Francais Du Fractionnement Composition d'immunoglobulines humaines stabilisee
US20120076779A1 (en) * 2010-09-17 2012-03-29 Baxter Healthcare S.A. STABILIZATION OF IMMUNOGLOBULINS AND OTHER PROTEINS THROUGH AQUEOUS FORMULATIONS WITH SODIUM CHLORIDE AT WEAK ACIDIC TO NEUTRAL ph
SG193963A1 (en) * 2011-04-07 2013-11-29 Glaxosmithkline Llc Formulations with reduced viscosity
CN108771655A (zh) 2011-10-28 2018-11-09 诚信生物公司 含有氨基酸的蛋白质制剂
US9592289B2 (en) 2012-03-26 2017-03-14 Sanofi Stable IgG4 based binding agent formulations
EP4527855A3 (en) * 2012-03-26 2025-06-11 Sanofi Stable igg4 based binding agent formulations
JP6224586B2 (ja) * 2012-07-10 2017-11-01 武田薬品工業株式会社 注射用製剤
EP2877589B1 (en) 2012-07-26 2024-03-06 Momenta Pharmaceuticals, Inc. Glycoproteins with anti-inflammatory properties
US8613919B1 (en) 2012-08-31 2013-12-24 Bayer Healthcare, Llc High concentration antibody and protein formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
EP2900262A1 (en) * 2012-09-27 2015-08-05 Octapharma AG Test for hemolytic potential of pharmaceutical products and formulations for risk minimization
US9700486B2 (en) 2013-04-24 2017-07-11 Corning Incorporated Delamination resistant pharmaceutical glass containers containing active pharmaceutical ingredients
WO2014186310A1 (en) 2013-05-13 2014-11-20 Momenta Pharmaceuticals, Inc. Methods for the treatment of neurodegeneration
IL312865B2 (en) 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
EP3125942B8 (en) * 2014-04-03 2021-12-01 CSL Behring AG Nebulization of immunoglobulin
US11357857B2 (en) 2014-06-20 2022-06-14 Comera Life Sciences, Inc. Excipient compounds for protein processing
WO2015196091A1 (en) 2014-06-20 2015-12-23 Reform Biologics, Llc Viscosity-reducing excipient compounds for protein formulations
US10478498B2 (en) 2014-06-20 2019-11-19 Reform Biologics, Llc Excipient compounds for biopolymer formulations
AU2015325055B2 (en) 2014-10-01 2021-02-25 Eagle Biologics, Inc. Polysaccharide and nucleic acid formulations containing viscosity-lowering agents
ES2988823T3 (es) 2014-12-03 2024-11-21 Csl Behring Ag Producto farmacéutico con mayor estabilidad que comprende inmunoglobulinas
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
MX2018011675A (es) * 2016-03-25 2019-01-10 Astellas Pharma Inc Composicion farmaceutica que comprende un fragmento fab' pegilado de anticuerpo anti-ngf humano.
EP3254671B1 (en) 2016-06-10 2019-11-13 Octapharma AG High concentration immunoglobulin composition for pharmaceutical application
PT3528787T (pt) 2016-10-21 2026-03-11 Amgen Inc Formulações farmacêuticas e métodos para produzir as mesmas
EA202192860A1 (ru) * 2019-04-18 2021-12-23 Янссен Байотек, Инк Сиалилированные гликопротеины
TW202602486A (zh) 2024-03-07 2026-01-16 瑞士商Ｃｓｌ貝林股份有限公司 免疫球蛋白組成物及產生氣溶膠之方法

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2364792A1 (de) 1973-01-15 1974-07-18 South African Inventions Verfahren zum reinigen von gammaglobulin
JPS5420124A (en) 1977-07-14 1979-02-15 Green Cross Corp:The Preparation of gamma-globulin intravenous injection
US4186192A (en) 1978-12-18 1980-01-29 Cutter Laboratories, Inc. Stabilized immune serum globulin
US4362661A (en) 1979-08-09 1982-12-07 Teijin Limited Immunoglobulin composition having a high monomer content, and process for production thereof
JPS5731623A (en) 1980-07-30 1982-02-20 Morishita Seiyaku Kk Production of gamma-globulin for intravenous injection
JPS56127321A (en) 1980-03-10 1981-10-06 Mochida Pharmaceut Co Ltd Preparation of gamma-globulin pharmaceutical
JPS56135418A (en) 1980-03-27 1981-10-22 Green Cross Corp:The Heat treatment of aqueous solution containing 8 factor of coagulation of blood derived from human
JPS57128635A (en) 1981-01-30 1982-08-10 Morishita Seiyaku Kk Pharmaceutical preparation of gamma-globulin for venoclysis
US4360451A (en) * 1981-08-10 1982-11-23 Basf Wyandotte Corporation Amphoteric surfactant gels
US4396608A (en) * 1981-08-24 1983-08-02 Cutter Laboratories Intravenously injectable immune serum globulin
US4499073A (en) * 1981-08-24 1985-02-12 Cutter Laboratories, Inc. Intravenously injectable immune serum globulin
US4439421A (en) * 1982-08-30 1984-03-27 Baxter Travenol Laboratories, Inc. Stabilized gamma globulin concentrate
JPS6042336A (ja) 1983-08-18 1985-03-06 Nippon Seiyaku Kk 免疫グロブリンの製造方法
JPS60120823A (ja) 1983-12-02 1985-06-28 Green Cross Corp:The ＩｇＧ単量体
US4597966A (en) 1985-01-09 1986-07-01 Ortho Diagnostic Systems, Inc. Histidine stabilized immunoglobulin and method of preparation
JPH0825902B2 (ja) 1985-02-21 1996-03-13 株式会社ミドリ十字 γ−グロブリンの加熱処理方法
JPH0825903B2 (ja) 1985-05-16 1996-03-13 株式会社ミドリ十字 γ―グロブリン含有水溶液
GB8628104D0 (en) * 1986-11-25 1986-12-31 Connaught Lab Pasteurization of immunoglobin solutions
DE3641115A1 (de) * 1986-12-02 1988-06-16 Lentia Gmbh Verfahren zur herstellung eines intravenoes anwendbaren und in fluessiger form stabilen immunglobulins
HUT54308A (en) 1989-04-04 1991-02-28 Lilly Co Eli Process for producing immunoglobulin conjugates and medicaments comprising same
JPH0341033A (ja) † 1989-07-07 1991-02-21 Kyowa Hakko Kogyo Co Ltd 安定なモチリン類含有製剤
US5945098A (en) * 1990-02-01 1999-08-31 Baxter International Inc. Stable intravenously-administrable immune globulin preparation
US5177194A (en) * 1990-02-01 1993-01-05 Baxter International, Inc. Process for purifying immune serum globulins
ES2074490T5 (es) 1990-03-22 2004-02-16 Biotest Pharma Gmbh Procedimiento para la elaboracion de un preparado de inmunoglobulina g tolerable por via intravenosa.
JPH04346934A (ja) 1991-05-24 1992-12-02 Green Cross Corp:The γ−グロブリンの液状製剤
DE4118912C1 (pl) 1991-06-08 1992-07-02 Biotest Pharma Gmbh, 6072 Dreieich, De
DE4126983A1 (de) * 1991-08-15 1993-02-18 Boehringer Mannheim Gmbh Verfahren zur herstellung von humanprotein-enthaltenden, konservierten arzneimitteln fuer infusions- oder injektionszwecke
JP2942412B2 (ja) 1991-12-26 1999-08-30 鐘紡株式会社 化粧料
FR2706466B1 (fr) 1993-06-14 1995-08-25 Aetsrn Concentré d'immunoglobulines G à usage thérapeutique et procédé de production dudit concentré.
DE59309332D1 (de) * 1993-12-27 1999-03-04 Rotkreuzstiftung Zentratrallab Verfahren zur Herstellung eines Konzentrates von Anti-D-Immunoglobulin G und pharmazeutische Zusammensetzung, die dieses enthält
JPH07238036A (ja) 1994-02-28 1995-09-12 Green Cross Corp:The 静注用グロブリン液状組成物のグロブリン二量体増加抑制方法
GB9418092D0 (en) * 1994-09-08 1994-10-26 Red Cross Found Cent Lab Blood Organic compounds
JP3765108B2 (ja) 1994-09-30 2006-04-12 三菱ウェルファーマ株式会社 静脈注射用グロブリン製剤
EP0792294A1 (en) 1994-11-16 1997-09-03 Baxter International Inc. Human antibodies to t-cell receptor peptides and methods for their preparation
GB9610992D0 (en) * 1996-05-24 1996-07-31 Glaxo Group Ltd Concentrated antibody preparation
TW491855B (en) 1996-08-07 2002-06-21 Csl Ltd Purification of immunoglobulins
EP0852951A1 (de) * 1996-11-19 1998-07-15 Roche Diagnostics GmbH Stabile lyophilisierte pharmazeutische Zubereitungen von mono- oder polyklonalen Antikörpern
TR199901968T2 (xx) * 1996-12-24 1999-12-21 Biogen, Inc. Sabit s�v� interferon form�lleri.
US6171586B1 (en) * 1997-06-13 2001-01-09 Genentech, Inc. Antibody formulation
US5886154A (en) 1997-06-20 1999-03-23 Lebing; Wytold R. Chromatographic method for high yield purification and viral inactivation of antibodies
CN1149100C (zh) 1997-10-23 2004-05-12 三菱制药株式会社 可室温贮存的免疫球蛋白静脉注射制剂
US6162904A (en) * 1997-12-24 2000-12-19 Alpha Therapeutic Corporation Manufacturing method for intraveneously administrable immune globulin and resultant product
IL140155A (en) 1998-06-09 2005-12-18 Statens Seruminstitut Process for producing immunoglobulins for intravenous administration and other immunoglobulin products
SE0001128D0 (sv) 2000-03-30 2000-03-30 Amersham Pharm Biotech Ab A method of producing IgG
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
WO2004084816A2 (en) † 2003-03-21 2004-10-07 Progenics Pharmaceuticals, Inc. IMPROVED CD4-IgG2 FORMULATIONS
EP1532983A1 (en) 2003-11-18 2005-05-25 ZLB Bioplasma AG Immunoglobulin preparations having increased stability
WO2011095543A1 (en) 2010-02-04 2011-08-11 Csl Behring Ag Immunoglobulin preparation
EP2361636A1 (en) 2010-02-26 2011-08-31 CSL Behring AG Immunoglobulin preparation and storage system for an immunoglobulin preparation

Also Published As

Publication number Publication date
WO2005049078A2 (en) 2005-06-02
AU2004290899B2 (en) 2009-11-19
DK1687028T4 (en) 2015-12-21
KR20060118495A (ko) 2006-11-23
AU2004290899A1 (en) 2005-06-02
KR20100090731A (ko) 2010-08-16
WO2005049078A3 (en) 2005-07-07
EP2364730B1 (en) 2016-04-13
KR100989288B1 (ko) 2010-10-22
US8906368B2 (en) 2014-12-09
CA2545939C (en) 2013-12-24
EP2364730A3 (en) 2012-05-30
KR20120060924A (ko) 2012-06-12
EP2364730A2 (en) 2011-09-14
EP1532983A1 (en) 2005-05-25
CA2545939A1 (en) 2005-06-02
DK1687028T3 (da) 2013-01-28
EP1687028B1 (en) 2012-10-24
EP1687028A2 (en) 2006-08-09
US20070122402A1 (en) 2007-05-31
DK2364730T3 (en) 2016-08-01
PL2364730T3 (pl) 2016-12-30
JP4644203B2 (ja) 2011-03-02
US20130102760A1 (en) 2013-04-25
ES2398241T5 (es) 2016-01-28
JP2007511566A (ja) 2007-05-10
EP1687028B2 (en) 2015-11-04
US8715652B2 (en) 2014-05-06
PL1687028T3 (pl) 2013-03-29
ES2580778T3 (es) 2016-08-26
ES2398241T3 (es) 2013-03-14

Similar Documents

Publication Publication Date Title
PL1687028T3 (pl) Preparaty immunoglobulin o zwiększonej stabilności
GB0324044D0 (en) Protein
GB0325038D0 (en) Protein
GB0302699D0 (en) Immunoglobulin
GB0326676D0 (en) Protein
GB0322998D0 (en) Protein
GB0326635D0 (en) Protein
GB0322762D0 (en) Protein
GB0302112D0 (en) Protein
GB0302773D0 (en) Protein
GB0302888D0 (en) Protein
GB0303938D0 (en) Protein
GB0305450D0 (en) Protein
GB0305829D0 (en) Protein
GB0307132D0 (en) Protein
GB0307409D0 (en) Protein
GB0328913D0 (en) Protein
GB0328746D0 (en) Protein
GB0328272D0 (en) Protein
GB0300719D0 (en) Protein
GB0326637D0 (en) Protein
GB0300717D0 (en) Protein
GB0325274D0 (en) Protein
GB0300089D0 (en) Protein
GB0315521D0 (en) Protein